For U.S. Residents Only
+|Aa|-

Indication for Renvela and Renagel

Renvela® (sevelamer carbonate) and Renagel® (sevelamer hydrochloride) are indicated for the control of serum phosphorus in patients

Important Safety Information for Renvela and Renagel

  • Sevelamer is contraindicated in patients with bowel obstruction.

Click here for additional Important Safety Information.

Please see full Prescribing Information for Renvela (PDF) or full Prescribing Information for Renagel (PDF).

Learn how Renvela can
help lower phosphorus levels.

Learn more

Learn how Renvela can help lower phosphorus levels.

Learn more

Learn more about the important role
of dialysis in treatment

Learn more

Learn how you can make smart food choices

Learn more

Learn how Renassist may
be able to help you access
your Renvela.

Learn more

Learn how Renassist may be able to help you access your Renvela.

Learn more

Browse our Patient Resource Library

Downloadable tools to help you get the most out of your treatment.

Start searching

RenValue

Right start. Real savings.

The RenValue coupon program helps cover the costs of Renvela for qualified patients with or without prescription insurance.

Learn more at Renassist.com

Renassist® Reimbursement Support

On average, most patients pay less than $7/month for their Renvela prescription. Learn more at Renassist.com.

Indication for Renvela and Renagel

Renvela® (sevelamer carbonate) and Renagel® (sevelamer hydrochloride) are indicated for the control of serum phosphorus in patients

Important Safety Information for Renvela and Renagel

  • Sevelamer is contraindicated in patients with bowel obstruction.
  • Caution should be exercised in patients with dysphagia, swallowing disorders, and severe gastrointestinal (GI) motility disorders, including severe constipation or major GI tract surgery.
  • Common adverse events reported with sevelamer include vomiting, nausea, diarrhea, dyspepsia, abdominal pain, flatulence, and constipation. Other events reported include pruritus, rash, fecal impaction and, less commonly, ileus, bowel obstruction, and bowel perforation.
  • Uncommon cases of difficulty swallowing the Renagel (sevelamer hydrochloride) or Renvela® (sevelamer carbonate) tablet have been reported. Caution should be exercised in these patients and consideration given to using Renvela® (sevelamer carbonate) suspension in patients with a history of difficulty swallowing.
  • Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take sevelamer.
  • Serum bicarbonate and chloride levels should be monitored.
  • Follow patients for reduced vitamins D, E, and K (coagulation parameters) and folic acid levels.
  • Patients should be informed to take sevelamer with meals and to adhere to their prescribed diets.

Please see full Prescribing Information for Renvela (PDF) or full Prescribing Information for Renagel (PDF).
Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.

The health information contained herein is provided for general education purposes only. Your healthcare professional is the single best source of information regarding your health. Please consult your healthcare professional if you have any questions about your health or treatment.